Highlights Spruce Biosciences, Inc.

Equities

SPRB

US85209E1091

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-08 EDT			5-day change	1st Jan Change
0.8455 ^USD	+5.75%		+19.42%	-71.14%

03-15	North American Morning Briefing : Inflation -2-	DJ
03-14	Top Midday Decliners	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : Inflation -2-	03-15	DJ
Spruce Biosciences 2023 Loss Narrows; to Cut 21% Workforce After Trial Misses Target; Shares Sink	03-13	MT
Spruce Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-13	CI
Spruce Biosciences, Inc. Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH	03-13	CI
Spruce Biosciences, Inc. Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia	01-22	CI
Spruce Biosciences Reports Baseline Characteristics from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH	01-05	CI
Spruce Biosciences, Inc. Provides Clinical Program Updates and Outlook for 2024	01-04	CI
Spruce Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Spruce Biosciences, Inc. Completes Target Enrollment of CAHmelia-203 Study in Adult Classic Congenital Adrenal Hyperplasia	23-10-18	CI
Spruce Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Spruce Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
SPRUCE BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-16	AQ
Spruce Biosciences Provides Clinical Program Updates	23-01-09	CI
North American Morning Briefing : Stock Futures Soft as Investors Eye Jobs Report	23-01-06	DJ
Spruce Biosciences, Kaken Sign Licensing Deal for Tildacerfont in Japan; Spruce Shares Surge After Hours	23-01-05	MT
Spruce Biosciences and Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan	23-01-05	CI
SPRUCE BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22-11-10	AQ
Spruce Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
SPRUCE BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22-08-10	AQ
Spruce Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Spruce Biosciences, Inc.

Equities

SPRB

US85209E1091

Highlights

Filters